We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.57B
AUM Growth
-$21.5M
Cap. Flow
+$32.3M
Cap. Flow %
1.25%
Top 10 Hldgs %
39.02%
Holding
197
New
37
Increased
49
Reduced
41
Closed
10

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$39M
2
JNJ icon
Johnson & Johnson
JNJ
+$21.2M
3
ESPR
Esperion Therapeutics
ESPR
+$13.9M
4
ABBV icon
AbbVie
ABBV
+$11.5M
5
BMY icon
Bristol-Myers Squibb
BMY
+$11.4M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$36.3M
2
AMGN icon
Amgen
AMGN
+$29.7M
3
BIIB icon
Biogen
BIIB
+$20.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$19.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.47%
2 Real Estate 2.71%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
176
DELISTED
Adamas Pharmaceuticals
ADMS
$399K 0.02%
+16,699
New +$526K
CAH icon
177
Cardinal Health
CAH
$53.2B
$395K 0.02%
6,300
– –
BLCM
178
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$394K 0.02%
6,000
– –
NTUS
179
DELISTED
Natus Medical Inc
NTUS
$381K 0.01%
+11,335
New +$359K
ADYX
180
DELISTED
Adynxx Inc
ADYX
$318K 0.01%
27,500
– –
CLDX icon
181
Celldex Therapeutics
CLDX
$3.02B
$247K 0.01%
7,053
– –
AGIO icon
182
Agios Pharmaceuticals
AGIO
$1.95B
$230K 0.01%
+2,810
New +$217K
JNCE
183
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$226K 0.01%
+10,127
New +$225K
TBPH icon
184
Theravance Biopharma
TBPH
$873M
$196K 0.01%
+8,083
New +$222K
QHC
185
DELISTED
Quorum Health Corporation
QHC
$194K 0.01%
23,725
– –
ADVM
186
DELISTED
Adverum Biotechnologies
ADVM
– –
-74,397
Closed -$2.6M
BCRX icon
187
BioCryst Pharmaceuticals
BCRX
$2.35B
– –
-449,255
Closed -$2.21M
DXCM icon
188
DexCom
DXCM
$28.8B
– –
-215,800
Closed -$3.1M
KPTI icon
189
Karyopharm Therapeutics
KPTI
$159M
– –
-1
Closed –
LRMR icon
190
Larimar Therapeutics
LRMR
$397M
– –
-1,109
Closed -$61K
CYTO
191
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-10
Closed -$457K
NUVA
192
DELISTED
NuVasive, Inc.
NUVA
– –
-117,437
Closed -$6.87M
IPXL
193
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-124,335
Closed -$2.07M
CASC
194
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-740,769
Closed -$2.74M
AGN.PRA
195
DELISTED
Allergan plc
AGN.PRA
– –
-5,000
Closed -$2.93M
4 5 6 7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Tekla Capital Management held 197 positions worth $2.57B, down 0.83% from $2.59B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q1 2018 filing shows 37 new, 49 increased, 41 reduced and 10 closed positions. Its largest new stake was Esperion Therapeutics: 189,287 shares worth $13.7M. The largest sale was Gilead Sciences, an estimated $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q1 2018 buy was Esperion Therapeutics: 189,287 shares worth $13.7M.
  • Tekla Capital Management added most to Pfizer in Q1 2018, an estimated $39M increase.
  • Tekla Capital Management's biggest Q1 2018 reduction was Gilead Sciences, cutting an estimated $36.3M.
  • Tekla Capital Management fully exited NuVasive, Inc. in Q1 2018, selling an estimated $6.87M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.57B portfolio in Q1 2018.
  • Tekla Capital Management opened 37 new positions and closed 10 in Q1 2018.
  • Tekla Capital Management's portfolio value fell 0.83% quarter-over-quarter to $2.57B.

Based on Tekla Capital Management's 13F filing for Q1 2018, filed 14 May 2018.